KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition

Sorafenib, a multikinase inhibitor, is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, resistance to this regimen is frequently observed in clinical practice, and the molecular basis of this resistance remains largely unknown. Herein, the antitumor activi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Cancer
Autori principali: Hu, Bo, Cheng, Jian-Wen, Hu, Jin-Wu, Li, Hong, Ma, Xiao-Lu, Tang, Wei-Guo, Sun, Yun-Fan, Guo, Wei, Huang, Ao, Zhou, Kai-Qian, Gao, Ping-Ting, Cao, Ya, Qiu, Shuang-Jian, Zhou, Jian, Fan, Jia, Yang, Xin-Rong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2019
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692625/
https://ncbi.nlm.nih.gov/pubmed/31417635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.31448
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi